Nutramax Laboratories Consumer Care, Inc. today announced the results of a six-week, open-label pilot study that found Cosamin®ASU, the company's advanced joint health formulation, is effective in reducing concentrations of serum and urine biomarkers associated with joint discomfort and cartilage breakdown. The study, carried out by researchers at the University of Missouri, also included clinical assessments which found that Cosamin ASU may be associated with improvements in measures of function and quality of life.